Pediatric Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Treatment Studies, Observational Studies), By Therapeutic Areas (Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Pediatric Clinical Trials Market Size

The global pediatric clinical trials market size was valued at USD 20.49 billion in 2025 and is projected to grow from USD 21.53 billion in 2026 to USD 32.06 billion by 2034, registering a CAGR of 5.1% during the forecast period from 2026 to 2034. North America dominated the pediatric clinical trials market with a market share of 42% in 2025.

For a variety of indications that affect children, paediatric clinical trials are the only criteria for releasing new drugs onto the market. As a result, pharmaceutical and biotechnological industries have been shifting away from in-house clinical research and toward contracts with contract research organisations (CRO).

Due to unmet medical requirements in the paediatric population, there is a large product pipeline in the clinical stage of development. In the near future, the pharmaceutical industry will benefit greatly from a strong pipeline of new drugs being developed. A growing awareness about pediatric medicine, a shift away from conducting clinical trials in-house and toward contract research organisations (CROs), and an increasing burden of pediatric diseases like diabetes are the primary factors driving the expansion of the market for paediatric clinical trials. It is anticipated that the market for pediatric clinical trials would demonstrate consistent growth over the course of the next years due to the expanding significance of pediatric medicine.

The Global Pediatric Clinical Trials Market is divided into different segments according to the Phase, Study Design, Therapeutic Areas, and Region (Geography).

Phase Analysis

The Global Pediatric Clinical Trials Market is segmented into Phase I, Phase II, Phase III, and Phase IV. In 2021, the phase II trials market segment held the largest market share, contributing more than 35% of worldwide revenue. Children are used in phase II trials to examine the intervention's safety and effectiveness. Pediatric participants make up a large portion of phase II trials, which are also more difficult than phase I studies. Children are typically not tested for medicinal products until phase III of the trials, which looks at the efficacy, acceptability, and side effects.

Although the deferral is meant to protect children from unwarranted harm, it also suggests that children's access to potentially beneficial treatments would be postponed. During the projected period, the phase IV segment is anticipated to increase at the quickest rate, exceeding 5.00%. Rarely are pediatric phase IV post-marketing trials carried out. Pediatric studies for marketed medications are necessary, nonetheless, according the FDA's Pediatric Research Equity Act (PREA).

Request Customizationto receive a tailored report.

Study Design Insights

The Global Pediatric Clinical Trials Market is segmented into Treatment Studies and Observational Studies. More than 67% of the global market's revenue in 2021 was attributable to treatment studies. Clinicaltrials.gov reports that a total of 53,060 pediatric trials were registered between 2000 and 2019; of those, 36,136 (68.1%) included therapy studies. However, there were fewer pharmacological studies carried out throughout time, and the majority of pediatric therapy trials were single site (61.4%), small-scale (58.9%), randomized (66.0%), and had no masking (56.9%).

Drug studies were the most prevalent observational trial category (40%) while behavioral treatment trials climbed from 13 to 21%. The majority of funding for pediatric therapy studies comes from institutions (80%), industry (20%), the National Institutes of Health (NIH) (2%), and U.S. federal agencies (0.5%). The industry-funded trials, whether single-site or multi-site, were also finished more frequently and had a stronger treatment emphasis. On the other hand, behavioral and "other" intervention treatments predominated in NIH- and other-funded trials.

therapeutic Area Analysis

The Global Pediatric Clinical Trials Market is segmented into Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders, and Others. In terms of revenue share, the oncology therapeutic area sector ranked second globally in 2021 with a share of more than 20%. One of the leading causes of death in the globe is cancer. By 2040, it is predicted that 291,000 children under the age of 19 would have been diagnosed with cancer. The NCI's Young Cancer Data Initiative, which was introduced in 2019 to encourage data sharing and the gathering of fresh data among researchers who study childhood cancers, offers the Molecular Characterization Initiative.

The purpose of this government initiative is to provide researchers with data on pediatric cancer. It's a form of covert assistance that will accelerate the sector's expansion. Over the projected period, the category for mental health disorders is anticipated to develop at the fastest rate. One of the main causes of the significant demand for pediatric clinical trials for mental health disorders is the high frequency of CNS-related conditions in children, such as autism hyperactivity, migraine, seizures, and others. It is anticipated that financing for CNS-related clinical investigations from various public organizations would help this market segment grow even further.

Speak to an Analystto discuss market opportunities.

Regional Insights

The Global Pediatric Clinical Trials Market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America Dominates the Global Market

In 2021, the market in North America was the most lucrative and held the highest share, accounting for 45% of the total income generated worldwide. This is because the region is home to a sizeable population of pharmaceutical businesses as well as CROs that are actively engaged in the conduct of paediatric trials. In addition to this, public groups are also carrying out active measures in order to assist paediatric research. For example, the National Institutes of Health (NIH) is contributing $4 billion to paediatric research at the moment. These kinds of activities are contributing even more to the expansion of the market in this region.

It is predicted that the United States will continue to hold a large portion of the market throughout the projection period. There were more than 1,265 ongoing paediatric clinical trials in the United States as of June 2021, which represents a considerable part of the global number of paediatric research processes, according to clinicaltrials.gov. The U.S. market has been significantly impacted by the vast number of studies and high per-procedure and-patient costs. Clinical trials in the country are increasing as a result of a growing number of children being diagnosed with illnesses that could be treated with certain pharmaceuticals. According to the National Diabetes Statistics Report 2020, around 187,000 American children and adolescents have Type 1 diabetes in 2018, and this figure is expected to rise in the coming years.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Fastest-Growing Region

On the other side, it is anticipated that Asia Pacific would record the highest CAGR throughout the course of the forecast period. The Asia-Pacific area has quickly become a centre for the conduct of clinical trials as a result of the simplicity with which regulatory compliance may be achieved, the low costs of studies, and the constantly expanding paediatric patient population. In addition, supportive activities that promote paediatric research in the region are driving growth in the regional market. This is a direct result of the high prevalence of paediatric disorders in the region. According to a report published by UNESCO in March 2022, for instance, experts in China are concentrating on creating advancements in neuroscience in order to better treat autistic children in the country.

List of Key and Emerging Players in Pediatric Clinical Trials Market